iPSC Hepatocyte Differentiation via Sequential Media
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human induced pluripotent stem cells (iPSCs) into hepatocytes are inefficient, resulting in immature phenotypes and suboptimal hepatic function, limiting their clinical potential for liver disease treatment and organ replacement.
Innovation Solution
A method involving sequential culture of iPSCs in specific media containing activin A, fibroblast growth factor-2, bone morphogenic protein-4, dimethyl sulfoxide, hepatocyte growth factor, and other compounds to produce mesendoderm, definitive endoderm, hepatic progenitor cells, and finally human hepatocytes, with expansion in immunocompromised animals to achieve functional liver repopulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current differentiation methods are used to produce hepatocytes from iPSCs, then cell production is achieved, but the hepatocytes exhibit immature phenotype and suboptimal hepatic function
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: mesendoderm formation (days 0-3), definitive endoderm formation (days 3-6), hepatic progenitor cell formation (days 6-12), and mature hepatocyte maturation (days 12-21). Each stage uses specific growth factor combinations and medium conditions to guide progressive maturation, ensuring functional competence at each transition point while maintaining overall production efficiency.
Solution Approach 2:
The protocol performs preliminary actions by pre-specifying the differentiation trajectory through staged growth factor exposure. Mesendoderm cells are pre-prepared with specific signaling molecule exposure patterns that prime them for subsequent hepatocyte maturation, ensuring that cells are properly programmed before final differentiation occurs, thereby guaranteeing functional quality.
2Manufacturing precision
If protocols direct differentiation of iPSCs into hepatocytes, then hepatocyte production is achieved, but the cells show immature phenotype limiting clinical potential
Solution Approach 1:
The protocol systematically changes multiple parameters throughout the differentiation process: growth factor concentrations (activin A, BMP4, FGF2, HGF), medium composition (low glucose vs. high glucose), and time duration at each stage. These parameter transitions guide cells from pluripotent state through intermediate stages to mature hepatocytes, ensuring precise maturation control despite protocol complexity.
Solution Approach 2:
The protocol uses intermediate cell states as mediators in the differentiation pathway. Mesendoderm cells and definitive endoderm cells serve as necessary intermediate stages that bridge iPSCs and mature hepatocytes. These intermediary states ensure proper developmental programming and functional maturation, acting as controlled transition points that guarantee final cell quality.
3Reliability
If more differentiation stages are implemented to improve hepatocyte maturity, then functional quality improves, but production time and process complexity increase
Solution Approach 1:
The differentiation protocol maintains continuous useful action by ensuring that each stage transitions smoothly into the next without interruption. Cells progress continuously through mesendoderm → definitive endoderm → hepatic progenitor → mature hepatocyte stages with appropriate growth factor exposure at each transition, minimizing idle time while ensuring complete maturation for functional quality.
Data Source
Figure 1
Figure 2~3
Figure 4A~4B
AI summary
Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.